Palo Azul (Eysenhardtia polystachya): An Encyclopedic Reference
1. Identity and Botanical Classification
Botanical Name and Taxonomy
Palo Azul is scientifically known as Eysenhardtia polystachya (Ortega) Sarg., a deciduous tree found in warm areas from Southeastern Arizona extending southward to Oaxaca, Mexico. The Eysenhardtia genus belongs to the family Fabaceae (Leguminosae), subfamily Papilionoideae. Recognized synonyms for the species include Eysenhardtia amorphoides, Dalea fruticosa, Psoralea fruticosa, and Viborquia polystachya.
The tree is also known by numerous common and indigenous names, including: "Palo azul" (Blue stick), "Palo dulce" (Sweet stick), Varaduz, Tlapahuaxpatli, Coathli, and Lignum nephriticum (in historical European texts). In the United States, it is commonly called kidneywood. In the Nahuatl dialect, it is known as "tlapalezpatli," and in the Otomi dialect as "urza."
Morphology and Range
Eysenhardtia polystachya is a much-branched, deciduous shrub or small tree usually growing 1.5–5 metres tall, occasionally reaching 7 metres, with a bole that can be up to 25 cm in diameter. The tree has rough, scaly bark that is dark on the outside and reddish-brown on the inside, with compound leaves made up of small elliptical leaflets. The wood contains aromatic resins. E. polystachya is characterized by a crown with multiple leaves in an alternating and elliptical arrangement in the shape of a bush and glandular trichomes that secrete aromatic resins. Its distribution spans the south, center, and north of Mexico to the southwestern United States, including Arizona, New Mexico, and Texas.
Common Preparations and Dosage Forms
Ethnobotanical surveys indicate the plant is called "palo dulce," "palo azul," and "hierba de la víbora." It is primarily used to treat kidney pain, urolithiasis, as a diuretic, and for renal infections. The plant is prepared as an infusion, decoction, or maceration, using one or two small pieces of the bark in one liter of water, taken orally as a tea until symptoms disappear. The infusion of bark, branches, and leaves produces a sweet flavor and shows a golden color. Commercial preparations sold in health markets, herbal shops, and online include dried wood chips or sticks, packaged tea bags, and powdered extracts.
2. Traditional and Historical Use
Pre-Hispanic Aztec Use
Mexico has a history of using ethnomedicine whose origins go back to pre-Hispanic cultures, where archaeological findings have shown its anthropological influence and impact on Mexican culture. One of the plants with the earliest antecedents is Eysenhardtia polystachya, dating back to the era of New Spain. An inspection of the works of sixteenth-century Spanish missionaries and scholars who compiled information on the Aztec culture, such as Fr. Bernardino de Sahagún and Francisco Hernández, indicates that pre-Hispanic Indian doctors had already noticed the blue color (fluorescence) of the infusion of "coatli," a wood used to treat urinary diseases. In the Florentine Codex, Fray Bernardino de Sahagún refers to the use of "Coatli" for fever or retention of urine.
The Lignum Nephriticum Tradition (16th–18th Centuries)
Historically, Eysenhardtia polystachya was known in Europe as Lignum nephriticum — Latin for "kidney wood" — prized for its diuretic properties in treating kidney and urinary disorders. The wood yields an infusion that turns blue in water and exhibits intense fluorescence under light, a phenomenon first documented in 1565 by Spanish physician Nicolás Monardes, marking one of the earliest recorded observations of solution fluorescence.
Introduced to Europe from the New World during the 16th century, lignum nephriticum was celebrated in medical texts for its therapeutic virtues, including relief from urinary stones and infections, as described by Aztec healers and later European scholars like Monardes in his Historia medicinal de las cosas que se traen de nuestras Indias Occidentales. This phenomenon was further described by Monardes, who noted the wood's ability to impart opalescent colors to water. Robert Boyle further investigated it in 1663, observing that the color variability arises from the extract's interaction with light and its sensitivity to chemical additives.
Because of its almost miraculous optical properties, the wood became very popular throughout Europe in the 16th, 17th, and the early part of the 18th centuries, and was the subject of investigations by the most celebrated physicists of that period. Cups made from lignum nephriticum were given as gifts to royalty. It was eventually recognized that the historical name actually confused two different tree species: the original traditional remedy described by Monardes came from Mexican kidneywood (Eysenhardtia polystachya), while the cups that became famous in Europe were carved from narra wood (Pterocarpus indicus), imported into Mexico from the Philippines via the Manila–Acapulco Galleon trade. This botanical confusion was not definitively resolved until the American botanist William Edwin Safford correctly re-identified the species in 1914–1915.
Mexican Traditional Medicine
E. polystachya is used in Mexican traditional medicine as a diuretic, anti-inflammatory, spasmolytic, wound-healing, and anticonceptive agent; it is also employed for the empirical treatment of genitourinary infections, cancer, arthritis, diarrhea, fever, cough, vomiting, bronchitis, and bladder disorders. E. polystachya is widely used in folk medicine as a blood depurative, antitussive, antispasmodic, antidiabetic, febrifuge, anti-inflammatory, anti-rheumatic, and analgesic agent. In Mexico, traditional herbal medicine has been used as an alternative for communities with limited access to medical care due to deficiencies in the national health system.
3. Key Phytochemical Constituents
Overview of Chemical Classes
The Eysenhardtia genus has been shown to be an excellent source of secondary metabolites, with flavonoids, flavones, isoflavones, flavanones, phenolic compounds, chalcones, dihydrochalcones, coumarins, pterocarpans, sugars, and fatty acids, among others, in its composition. Phytochemical screening of the extract has revealed the presence of additional medicinal active constituents including anthraquinones, cardiac glycosides, coumarins, reducing sugars, saponins, and tannins.
Coatline A and Coatline B
Studies have isolated the chalcones coatline A, coatline B, and several related α-hydroxydihydrochalcone derivatives from the bark and trunks of E. polystachya. The wood of Eysenhardtia polystachya contains large quantities of Coatline B, a rare C-glucosyl-α-hydroxydihydrochalcone. This compound gives rise to a fluorescent reaction product in slightly alkaline water at room temperature, which is responsible for the blue emission of the Lignum nephriticum infusion.
Matlaline: The Fluorescent Compound
The intense blue fluorescence of the infusion of Lignum nephriticum (Eysenhardtia polystachya), first observed in the sixteenth century, is due to a novel four-ring tetrahydromethanobenzofuro[2,3-d]oxacine compound — matlaline — which is not present in the intact plant but is the end product of an unusual, very efficient iterative spontaneous oxidation of at least one of the tree's flavonoids. Specifically, the flavonoids, particularly C-glucosyl-α-hydroxydihydrochalcones like Coatline B, undergo oxidative coupling during extraction to form matlaline, the fluorescent derivative responsible for the wood's optical properties. The fluorescent substance is currently known as matlaline.
Isoflavones
The plant contains polyphenols; in addition, 7-hydroxy-2′,4′,5′-trimethoxyisoflavone has been isolated as the principal fluorescent phenolic constituent of the heartwood. The compounds responsible for antiurolithiatic and diuretic activity were identified as 7-hydroxy-2′,4′,5′-trimethoxyisoflavone and 7-hydroxy-4′-methoxyisoflavone.
Additional Flavonoids
Six additional new flavonoids have been isolated from the bark of Eysenhardtia polystachya, including 2′,4′-dihydroxychalcone-6′-O-β-d-glucopyranoside, α,3,2′,4′-tetrahydroxy-4-methoxy-dihydrochalcone-3′-C-β-glucopyranosy-6′-O-β-d-glucopyranoside, and several coumarin- and pterocarpan-class compounds. Other phenolic compounds including (3S)-7-hydroxy-2′,3′,4′,5′,8-pentamethoxyisoflavan, (3S)-3′,7-dihydroxy-2′,4′,5′,8-tetramethoxyisoflavan, and soduartin have been reported from the plant.
D-Pinitol
The main component identified in an ethanol extract of E. polystachya branches and leaves (EPE) by GC-MS was D-pinitol, at 26.93% of total identified compounds. D-pinitol has been reported to exert antidiabetic, antitumor, and anti-inflammatory effects, among others. D-pinitol is a naturally occurring cyclitol (a methylated inositol) found in several leguminous plants and has independently been studied for its metabolic effects.
4. Mechanisms of Action
Antioxidant and Reactive Oxygen Species Scavenging
Studies of E. polystachya extracts have demonstrated the ability to decrease and/or eliminate free radicals (DPPH, ABTS) as well as reactive oxygen species (RO₂, −O₂, H₂O₂, −OH, ONOO−, NO, HOCl, ¹O₂), with metal-chelating ability and reduced lipoperoxidation. Inhibition of fluorescent advanced glycation end-products (AGEs), glycation of hemoglobin, and methylglyoxal-mediated glycation has also been examined.
Nephroprotective Pathways
Coatline B and Matlaline exhibit antioxidant activity and play a role in nitric oxide (NO) and hydrogen sulfide (H₂S) regulation pathways as mediators of inflammation in renal tissue. Their use as prophylactic agents in an acute kidney injury (AKI) model reduces renal tissue damage and prevents a severe decline in kidney function.
Anti-Inflammatory Cytokine Modulation
Ethanolic extract of bark (EE) and its flavonoid-rich fractions inhibited secondary inflammatory reactions, diminished specific histopathological alterations in the joint capsule, and reduced serum concentrations of the pro-inflammatory cytokines IL-6, TNF-α, and GM-CSF in arthritic rats. In vitro anti-inflammatory effects were demonstrated by the decrease in production of H₂O₂ (IC₅₀ = 43.9 ± 3.8 µg/ml) and IL-6 (73.3 ± 6.9 µg/ml).
Antinociceptive Mechanisms
Research results suggest that E. polystachya exerts its antinociceptive action due to the participation of ATP-sensitive K⁺ channels. D-pinitol inhibited pain with an effective dose of 10.7 mg/kg; its activity is associated with the serotonergic system (5-HT3) and nitric oxide.
Antiurolithiatic Mechanisms
In preclinical studies, isoflavones isolated from the bark of Eysenhardtia polystachya were found to inhibit the formation and growth of calcium oxalate monohydrate (COM) stones in urine, suggesting the use of these isoflavones as a preventive treatment for kidney stone formation.
Antiglycation Activity
A bioactive compound (3′-O-β-D-glucopyranosyl α,4,2′,4′,6′-pentahydroxy–dihydrochalcone) isolated from Eysenhardtia polystachya was demonstrated in 2019 to be an excellent antiglycation compound capable of reducing glycation of proteins responsible for diabetic nephropathy.
5. Scientific Evidence by Area of Use
The entirety of the published scientific evidence on Eysenhardtia polystachya consists of in vitro (cell/biochemical assays), in vivo animal studies, and ethnobotanical surveys. As of the date of this article, no controlled clinical trials in human subjects have been published specifically on palo azul preparations. All pharmacological findings described below are therefore preclinical.
5.1 Kidney and Urinary System
Eysenhardtia polystachya has a long history of use in traditional Mexican and Central American herbal medicine, particularly as a remedy for kidney and urinary tract health. Folk practitioners commonly prepare Palo Azul as a tea, claiming benefits such as diuretic action, relief from urinary discomfort, and prevention of kidney stones. Historical accounts and ethnobotanical surveys consistently cite its use for these purposes among indigenous and rural populations.
Diuretic Activity (Animal Study): A 1998 animal study tested the diuretic and antilytic effect of the aqueous extract of Eysenhardtia polystachya bark in rats. Model animals were induced with urolithiasis by implanting a zinc disk in the bladder. A significant reduction in the weight of uroliths was observed after administration of the aqueous extract compared to the control group.
Dose-Response Diuretic Study (Animal): A study evaluated diuretic activity of the bark aqueous extract at doses of 125, 250, 500, and 750 mg/kg body weight, as well as furosemide (4 mg/kg) and vehicle, administered orally to female rats (n = 6 per group). After 6 hours in metabolic cages, effects on urinary flow, glomerular filtration rate, and electrolyte balance of sodium and potassium were assessed. E. polystachya at doses of 500 and 750 mg/kg induced diuretic activity, markedly increasing urinary flow rate (p < 0.05) similar to the furosemide-treated group.
Antiurolithiatic Activity (Animal/In Vitro): In 2002, the effect of isoflavones isolated from the bark of Eysenhardtia polystachya on the formation of oxalate and calcium phosphate (COM) stones was analyzed in a preclinical trial. The phenolic compounds were able to inhibit the formation and growth of COM, reducing the appearance of kidney stones and suggesting isoflavones as a preventive treatment.
Nephroprotective Activity (In Vivo/In Vitro, 2025): In a 2025 study, a methanolic extract was obtained from which Coatline B and Matlaline were isolated and identified. Their pharmacological activity was evaluated as potential nephroprotective agents using both in vivo and in vitro models of AKI. Coatline B and Matlaline exhibited antioxidant activity and played a role in nitric oxide (NO) and hydrogen sulfide (H₂S) regulation pathways as mediators of inflammation in renal tissue. Their use as prophylactic agents reduced renal tissue damage and prevented severe decline in kidney function.
Evidence Strength: Preclinical only. Animal and in vitro data are consistent and mechanistically plausible, but no human clinical trials have been conducted. The diuretic effect in rats has been replicated, and the antiurolithiatic mechanism has been isolated to specific isoflavone compounds. Translation to human efficacy remains unestablished.
5.2 Antidiabetic and Metabolic Activity
Antidiabetic Activity (Animal/In Vitro, 2014): A 2014 study evaluated the antidiabetic, antioxidant, and antiglycation properties of Eysenhardtia polystachya bark methanol-water extract. Antioxidant capacities were evaluated by in vitro scavenging of DPPH and ABTS free radicals and reactive oxygen species. Antiglycation activities were evaluated using hemoglobin and bovine serum albumin (BSA)-glucose assays. Oral administration of EP at doses of 100 mg/kg, 200 mg/kg, and 400 mg/kg was studied in normal, glucose-loaded, and streptozotocin-induced mildly and severely diabetic mice. Results indicated that Eysenhardtia polystachya possesses considerable antioxidant activity with reactive oxygen species scavenging activity and demonstrated anti-AGE and hepatoprotective roles, and inhibited hyperglycemic, hyperlipidemic, and oxidative stress, suggesting these effects may be mediated by interacting with multiple targets in diabetes mellitus.
Flavonoid Antidiabetic Activity (Animal, 2016): The antidiabetic activity of five newly isolated flavonoid compounds from E. polystachya bark was evaluated in terms of cellular antioxidant and free radical scavenging activity, and in streptozotocin-induced diabetic mice, measuring liver transaminases, lipid peroxidation, total bilirubin, total protein, superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (CSH-Px), and glutathione reductase (GSH).
Antiglycation Activity (In Vitro, 2019): In 2019, it was demonstrated that a bioactive compound isolated from Eysenhardtia polystachya is an excellent antiglycation compound capable of reducing glycation of proteins responsible for diabetic nephropathy in diabetic individuals.
Nanoparticle-Mediated Effects (Animal/In Vitro): When silver nanoparticles functionalized with E. polystachya extract (EP/AgNPs) were administered to glucose-induced diabetic zebrafish (111 mM), they showed improvement in levels of blood glucose, insulin, triglycerides, and cholesterol, helping to regulate hyperglycemic, hyperlipidemic, and insulin sensitivity. The authors suggested the possibility of using E. polystachya nanostructures as an alternative therapy for diabetes control due to their high concentration of chalcones, dihydrochalcones, and flavonoids.
Evidence Strength: Entirely preclinical (in vitro and animal models). No human trials exist. Results are mechanistically consistent across multiple study types, but extrapolation to human antidiabetic efficacy is premature.
5.3 Anti-Inflammatory and Antinociceptive Activity
Rheumatoid Arthritis (Animal, 2018): A 2018 study evaluated the anti-arthritic and antinociceptive properties of an ethanolic extract of E. polystachya (EE) bark and its flavonoid-rich fractions in murine models. EE was administered orally at doses of 25, 50, 100, and 200 mg/kg/day, and fractions at 25 mg/kg/day. Anti-arthritic activity was evaluated using a complete Freund's adjuvant (CFA)-induced rheumatoid arthritis model in rats. The severity of arthritis was evaluated by changes in paw edema, body weight, arthritic index, radiological scores, histological assessment of synovial joints, erythrocyte sedimentation rate, hematocrit, hemoglobin, serum rheumatoid factor, serum C-reactive protein, and serum levels of pro-inflammatory cytokines IL-1β, IL-6, TNF-α, IL-18, IFN-γ, and GM-CSF, and anti-inflammatory cytokines IL-4, IL-10, and IL-13. EE and its flavonoid-rich fractions inhibited secondary inflammatory reactions, diminished specific histopathological alterations in the joint capsule, and reduced serum concentrations of the pro-inflammatory cytokines IL-6, TNF-α, and GM-CSF in arthritic rats. EE also reduced the number of writhes produced by acetic acid and increased response time on the hot plate in mice. These findings support the use of Eysenhardtia polystachya bark for the treatment of rheumatoid arthritis and pain management.
Antinociceptive Mechanisms (Animal, 2018): In pharmacological testing, the ethanol extract of E. polystachya (EPE) showed antidiarrheal activity with an ED₅₀ of 7.5 ± 0.9 mg/kg and antinociceptive effects in the acetic acid test with an ED₅₀ of 117 ± 14.5 mg/kg for EPE; D-pinitol showed even higher potency (ED₅₀ = 33 ± 3.2 mg/kg). EPE also showed antinociceptive activity in the phase 2 of the formalin test (ED₅₀ = 48.9 ± 3.9 mg/kg), without inducing hypnotic effects or altering locomotor activity in mice.
D-Pinitol Antinociception (Animal): D-pinitol isolated from the ethanolic extract of E. polystachya was found to inhibit pain by 67.58% with an effective dose of 10.7 mg/kg; its activity is associated with the serotonergic system (5-HT3) and nitric oxide.
Evidence Strength: Preclinical only (animal models and in vitro). Anti-inflammatory and antinociceptive mechanisms have been partially characterized at the molecular level, but no human pain or arthritis trials exist.
5.4 Antimicrobial Activity
The first report on antimicrobial activity of the Eysenhardtia genus was published in 1997, using minimal inhibitory concentration (MIC) tests. The ethanol extract of E. polystachya showed good antimicrobial effects against E. coli (MIC = 1.56 µg/ml) and S. aureus (MIC = 0.78 µg/ml), while in multi-drug resistant microorganisms, EPE showed MIC > 100 µg/ml. A study specifically corroborated the empirical use of homemade preparations of Eysenhardtia polystachya to treat urinary tract infections, finding a partial antimicrobial effect on bacteria causing UTIs.
Evidence Strength: Preliminary in vitro data only. Activity against common pathogens at low concentrations is noted, but there is no clinical data supporting use as an anti-infective in humans. Activity against multi-drug resistant organisms was not observed.
5.5 Antioxidant Activity
In nanomaterial studies, nanoparticles and plant extracts of E. polystachya increased the activity of the antioxidant enzymes (SOD, CAT, and GPx) and reduced the damage caused by reactive oxidative species (ROS), positively influencing total protein concentration while decreasing malondialdehyde (MDA) formation and lipoperoxidation. Nanostructures with a high content of phenolic compounds were proposed as a viable alternative in minimizing diabetic complications associated with oxidative stress.
The Eysenhardtia genus has shown potential activity in the control and mitigation of urinary disorders, diabetes, oxidative stress, protein glycosylation, microbial infections, inflammation, pain or discomfort, muscle contractions, cytotoxicity, or as a cellular or neuronal signaling modulator.
Evidence Strength: In vitro and animal evidence only. Antioxidant activity is pharmacochemically well-characterized, but human clinical relevance is undetermined.
6. Body Systems and Health Areas of Association
- Urinary and Renal System: Ethnobotanical surveys indicate the plant is used primarily for kidney pain (42%), urolithiasis (31%), diuresis (15%), anuria or oliguria (7%), and renal infection (5%). Preclinical evidence supports diuretic activity, antiurolithiatic properties, and nephroprotection at the molecular level.
- Metabolic/Endocrine System (Diabetes and Glycation): Preclinical evidence for antidiabetic, antihyperlipidemic, and antiglycation effects through multiple pathways, mediated primarily by polyphenolic flavonoids and D-pinitol.
- Musculoskeletal and Pain System: Folk medicine uses include blood depurative, antitussive, antispasmodic, antidiabetic, febrifuge, anti-inflammatory, anti-rheumatic, and analgesic applications. Preclinical data supports anti-arthritic and antinociceptive activity via cytokine modulation and K⁺ channel and serotonergic mechanisms.
- Immune/Inflammatory System: Modulation of pro-inflammatory cytokines (IL-6, TNF-α, GM-CSF) and oxidative mediators (H₂O₂) documented in animal and cell models.
- Antimicrobial: In vitro activity against gram-positive and gram-negative urinary tract pathogens; preliminary evidence only.
7. Fluorescence: A Historically Significant Physicochemical Property
An early observation of fluorescence was known to the Aztecs and was described in 1560 by Bernardino de Sahagún and in 1565 by Nicolás Monardes in the infusion known as lignum nephriticum. It was derived from the wood of two tree species, Pterocarpus indicus and Eysenhardtia polystachya. The chemical compound responsible for the fluorescence is matlaline, which is the oxidation product of one of the flavonoids found in this wood.
The intense blue fluorescence of the infusion of Lignum nephriticum (Eysenhardtia polystachya), first observed in the sixteenth century, is due to a novel four-ring tetrahydromethanobenzofuro[2,3-d]oxacine which is not present in the plant but is the end product of an unusual, very efficient iterative spontaneous oxidation of at least one of the tree's flavonoids. This compound, matlaline, is now of interest in biochemical research for its use as a fluorescent biosensor. Research on cell culture applications showed that at the concentrations used, the fluorescent compounds from E. polystachya are non-toxic materials.
The optical phenomenon — where the infusion appears blue-green in reflected light and yellow-orange in transmitted light — is a classic example of solution fluorescence. It holds the distinction of being one of the earliest documented observations of this physical phenomenon, predating formal scientific understanding of fluorescence by over 300 years.
8. Dosages Reported in Studies
The following dosages appear in published scientific studies; they are reported as used in those studies and all are from animal or in vitro models:
- In the antidiabetic/antioxidant mouse study (Gutierrez & Baez, 2014), oral administration was at doses of 100 mg/kg, 200 mg/kg, and 400 mg/kg in streptozotocin-induced diabetic mice.
- In the rheumatoid arthritis and antinociceptive murine model (Pablo-Pérez et al., 2018), the ethanolic bark extract was administered orally at doses of 25, 50, 100, and 200 mg/kg/day, and flavonoid fractions at 25 mg/kg/day.
- In the diuretic rat study, doses of 125, 250, 500, and 750 mg/kg body weight were tested orally; doses of 500 and 750 mg/kg produced significant diuretic activity comparable to furosemide (4 mg/kg).
- Antinociceptive ED₅₀ values were 117 ± 14.5 mg/kg for EPE and 33 ± 3.2 mg/kg for D-pinitol in the acetic acid test.
- D-pinitol showed antinociceptive activity at an effective dose of 10.7 mg/kg in mice.
No standardized or validated dosage for human use has been established in peer-reviewed literature. Traditional folk preparations typically involve decocting or infusing one or two pieces of bark in approximately one liter of water, though this has not been clinically characterized.
9. Safety Considerations
Preclinical Toxicology
The ethanol extract of E. polystachya branches and leaves (EPE) showed low in vitro toxicity (DNA damage in peripheral blood mononuclear cells [PBMC] only at concentrations higher than 200 µg/ml) and low in vivo toxicity (LD₅₀ > 2000 mg/kg both intraperitoneally and orally in mice). EPE lacked cytotoxic activity (IC₅₀ > 300 µg/ml) on human cancer cells.
The present investigation shows that the ethanolic extract does not produce death, and it can be concluded that Eysenhardtia polystachya is not orally toxic in the murine models tested. Overall, Eysenhardtia polystachya showed low toxicity on in vitro and in vivo models.
Genotoxicity Threshold
The in vitro and in vivo toxicity of EPE was evaluated using the comet assay in human peripheral blood mononuclear cells (PBMC) and the acute toxicity test in mice, respectively. DNA damage was only detected at concentrations above 200 µg/ml in vitro, well above concentrations expected in typical tea preparations.
Antimicrobial Resistance Considerations
While EPE showed good antimicrobial effects against E. coli (MIC = 1.56 µg/ml) and S. aureus (MIC = 0.78 µg/ml), in multi-drug resistant microorganisms, EPE showed MIC > 100 µg/ml, indicating substantially reduced efficacy against resistant strains.
Electrolyte Effects
In the rat diuretic study, urinary flow, glomerular filtration rate, and electrolyte balance of sodium and potassium were assessed after six hours. Significant diuretic activity was observed at 500 and 750 mg/kg. The study assessed, but does not fully detail in publicly available extracts, whether significant electrolyte perturbations accompanied the diuresis.
Human Safety Data
No controlled human safety studies, pharmacokinetic studies, drug interaction studies, or adverse event monitoring data have been identified in the peer-reviewed literature for palo azul or its isolated constituents (coatline A, coatline B, matlaline, or the whole extract). Despite the widespread use of herbal medicines, few scientific studies have been undertaken to ascertain the safety and efficacy of traditional remedies. The absence of documented human safety data means that the preclinical low-toxicity profile cannot be directly extended to assurance of human safety without further study.
No Known Interaction Data
No peer-reviewed data on drug-herb interactions involving palo azul or its isolated components have been identified. Given the plant's established in vitro inhibition of inflammatory cytokines and potential diuretic activity, theoretical pharmacodynamic interactions with diuretics, anti-inflammatory drugs, antidiabetic agents, and anticoagulants could be considered relevant for future study, though these interactions have not been documented in published research.
10. Current Research Status and Limitations
The scientific investigation of Eysenhardtia polystachya remains concentrated at the preclinical stage. The Eysenhardtia genus has shown potential activity in the control and mitigation of urinary disorders, diabetes, oxidative stress, protein glycosylation, microbial infections, inflammation, pain, muscle contractions, cytotoxicity, and as a cellular or neuronal signaling modulator. However, this potential is derived entirely from biochemical, cell-culture, and animal studies.
Key limitations of the existing research body include: (1) the absence of any randomized controlled human trials; (2) significant heterogeneity in extract types used across studies (aqueous, methanolic, ethanolic, and standardized extracts), making cross-study comparisons difficult; (3) lack of bioavailability, pharmacokinetic, or metabolic data in humans; (4) variable botanical sourcing and no established standardization criteria for commercial preparations; and (5) the fact that most phytochemical isolation studies use high-purity isolated compounds at doses that may not be achievable from traditional tea preparations.
The anti-arthritic and antinociceptive mechanisms of the bark of Eysenhardtia polystachya are not yet fully known. Flavonoids could be responsible, but other chemicals could be equally important, such as coumarins, quinones, saponins, and tannins, which have antiphlogistic and antinociceptive activities in other plant species.
References
Go back